Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
BMJ Open. 2022 Jul 14;12(7):e062623. doi: 10.1136/bmjopen-2022-062623.
Since disseminated intravascular coagulation (DIC) was first described, it has been considered a serious disease of the coagulation system and a major challenge to clinicians. Currently, several important knowledge gaps remain. The DANish Disseminated Intravascular Coagulation (DANDIC) Cohort Study will aim to answer questions regarding the incidence and mortality of patients with DIC including time trends. The study will also identify prognostic factors that may guide personalised prevention and treatment. Furthermore, the study will describe treatment patterns and the safety and effectiveness of various treatment modalities.
We will establish the DANDIC Cohort using data collected in daily clinical practice from the Central Denmark Region, which covers approximately 1.3 million residents. The study period will encompass 1 January 2011 through 1 July 2021. Potential DIC cases will be identified from the hospital laboratory database, based on coagulation biomarkers, and diagnoses will be adjudicated by medical experts. The dataset will be enriched with detailed clinical data from electronic medical charts on aetiologies, bleeding, microthrombus formation, organ failure, thrombosis, treatments and comorbidities. The dataset will also take advantage of in-hospital data with longitudinal information on laboratory records, transfusions, microbiology and treatments. It will be possible to merge this dataset with other unique Danish health registries with more than 10 years of virtually complete follow-up. The project will use state-of-the-art epidemiological and biostatistical methods.
The project has been approved by the Danish Patient Safety Authority (31-1521-452), the Central Denmark Region (1-45-70-83-21), the Danish Data Protection Agency (1-16-02-258-21) and all the hospital chairs. Register-based studies require no ethical approval in Denmark. The results will be disseminated in international peer-reviewed journals.
自弥散性血管内凝血(DIC)首次被描述以来,它一直被认为是一种严重的凝血系统疾病,也是临床医生面临的主要挑战。目前,仍存在一些重要的知识空白。丹麦弥散性血管内凝血(DANDIC)队列研究旨在回答关于 DIC 患者的发病率和死亡率问题,包括时间趋势。该研究还将确定可能指导个体化预防和治疗的预后因素。此外,该研究将描述治疗模式以及各种治疗方式的安全性和有效性。
我们将利用丹麦中部地区在日常临床实践中收集的数据建立 DANDIC 队列,该地区约有 130 万居民。研究期间为 2011 年 1 月 1 日至 2021 年 7 月 1 日。将根据凝血生物标志物从医院实验室数据库中确定潜在的 DIC 病例,并由医学专家对诊断进行裁决。数据集将通过电子病历中的详细临床数据得到丰富,这些数据包括病因、出血、微血栓形成、器官衰竭、血栓形成、治疗和合并症。数据集还将利用住院数据,其中包含有关实验室记录、输血、微生物学和治疗的纵向信息。可以将该数据集与其他具有超过 10 年几乎完整随访的独特丹麦健康登记处进行合并。该项目将使用最先进的流行病学和生物统计学方法。
该项目已获得丹麦患者安全局(31-1521-452)、丹麦中部地区(1-45-70-83-21)、丹麦数据保护局(1-16-02-258-21)和所有医院主席的批准。在丹麦,基于登记的研究不需要伦理批准。研究结果将在国际同行评议期刊上发表。